Venetoclax Makes Inroads Into More Hematologic Setting

Venetoclax Makes Inroads Into More Hematologic Setting

Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention mediante 2020 for positive reports from phase 3 clinical trials exploring its use per acute myeloid leukemia and multiple myeloma.

Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax (Venclexta) garnered attention per 2020 for positive reports from phase 3 clinical trials exploring its use per acute myeloid leukemia (AML) and multiple myeloma.

“A large [number] of patients with AML, including those [75 years or older] or those who have medical comorbidities, cannot tolerate existing treatment strategies, and the patients with AML who are ineligible for intensive chemotherapy often experience poor prognoses,” Courtney D. DiNardo, MD, MCSE, lead investigator and an associate professor con the Department of Leukemia at The University of Texas MD Anderson Cancer Center sopra Houston, said mediante a news release. 4 “We launched the Viale-Per trial preciso evaluate whether we could safely use verso combination therapy sicuro treat this critical patient population.”

The trial met its primary end point of overall survival (OS) superiority with venetoclax. The median OS was 14.7 months for the venetoclax group and 9.6 months with placebo, which represents a 34% reduction in the risk of death (HR, 0.66; 95% CI, 0.52-0.85; P < .001).>

Venetoclax also improved complete remission (CR) rates, which represented a key secondary end point. Corresponding rates of CR were 36.7% versus 17.9% (P < .001);>

Notable hematologic adverse events with venetoclax included thrombocytopenia, neutropenia, febrile neutropenia, debolezza, and leukopenia. Discontinuation rates were similar mediante the venetoclax and placebo arms (24% vs 20%). Pezzo interruptions puro allow for hematologic recovery occurred more frequently with venetoclax (TABLE 1 3 ).

“Key amministrazione guidelines include dosing interruptions between cycles sicuro allow for count recovery per the setting of per leukemia-free marrow and the use of granulocyte colony-stimulating factor as an adjunct to improve neutrophil count once verso patient is con remission,” DiNardo said.

Supportive care for patients receiving the venetoclax regimen, such as prophylactic antimicrobial agents, was recommend by the investigators. It was noted that there were per niente differences con quality-of-life measures between the 2 groups.

Myeloma Combinations With Venetoclax Per BELLINI, patients with relapsed/refractory multiple myeloma who had received 1 esatto 3 prior therapies were randomly assigned esatto bortezomib and dexamethasone plus either placebo (n = 97) or venetoclax (n = 194). 2

Median progression-free survival (PFS), the trial’s primary end point, was significantly improved with venetoclax at 22.4 months versus 11.5 months with placebo (HR, 0.63; 95% CI, 0.44-0.90; P = .01).

Despite the positive efficacy findings, troubling treatment-related mortality tempo emerged. Eight (4%) treatment-emergent fatal infections were reported with venetoclax, and 3 deaths were concluded preciso be related sicuro treatment. However, neither event was noted con the placebo group. These concerning findings elevated the importance of identifying patient subsets who derive the greatest benefit from this therapy regimen.

Subgroup analyses identified patient groups with distinct efficacy outcome improvement. Response rates were better per patients who had high BCL2 expression or t(11;14) translocation (TABLE 2 2 ), and these responses were some of the best and most durable ever reported durante phase 3 trials examining triplet therapies for multiple myeloma, the investigators said.

Considerations for Care

Looking at the composite results of these trials, the evidence suggest that venetoclax may be verso valuable tool mediante the broader precision medicine paradigm sopra specific hematologic cancer population subsets.

Notably, the investigators on BELLINI reviewed why the agent was particularly effective in patients with per specific cytogenetic profile. “Most of the existing therapies for multiple myeloma target cellular mechanisms that are crucial preciso plasma cells broadly, rather than targeting changes unique puro malignant myeloma cells,” wrote the investigators led by Shaji K. Kumar, MD, of Mayo Clinic durante Rochester, Minnesota. “Venetoclax, by virtue of its mechanism of action, is prezzo koko app more effective against multiple myeloma cells that are more dependent on BCL2 for survival. BCL2 dependency varies between patients and is affected by BCL2 protein family member expression and the presence of genetic abnormalities, such as t(11;14) translocation, thus offering the opportunity esatto develop per personalized treatment strategy in multiple myeloma.”

Another phase 1/2 study (NCT01794520), which was reported at the 2019 American Society of Hematology Annual Congresso & Exposition, showed similarly positive results with the combination of venetoclax and dexamethasone sopra patients with multiple myeloma and translocation t(11;14), where 35% of patients had a very good partial response or better. These results were recorded mediante per cohort that included verso majority of patients who were refractory esatto daratumumab (Darzalex). 5

Venetoclax Makes Inroads Into More Hematologic Setting

The phase 3 CAining venetoclax and dexamethasone sopra patients with relapsed/refractory myeloma, this time with a comparator arm of pomalidomide (Pomalyst) and dexamethasone.

Sopra AML, the placement of venetoclax con the frontline setting offers an optimal treatment option sicuro those who formerly had few options, but this treatment approach is still evolving.

“While this combination represents verso key advance per AML therapy, improving both remission and survival rates sopra newly diagnosed patients with AML, many unfortunately will still relapse,” DiNardo said. “Our next steps include an evaluation of azacitidine and venetoclax as verso backbone puro which additional novel therapeutics are being evaluated per particularly high-risk populations.”

2. Kumar SK, Harrison SJ, Corda M, et al. Venetoclax or placebo per combination with bortezomib and dexamethasone con patients with relapsed or refractory multiple myeloma (BELLINI): verso randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. Published online . doi:/S1470-2045(20)30525-8

3. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax durante previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629. doi:/ NEJMoa2012971

4. Combination therapy significantly improves survival outcomes for patients with acute myeloid leukemia. News release. The University of Texas MD Anderson Cancer Center. .

5. Kaufman JL, Gasparetto C, Schjesvold FH, et al. Phase I/II study evaluating the safety and efficacy of venetoclax mediante combination with dexamethasone as targeted therapy for patients with t(11;14) relapsed/refractory multiple myeloma. Blood. 2019;134(suppl 1):926. doi:/blood-2019-125871

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *